Nintedanib in Progressive Fibrosing Interstitial Lung Diseases

Kevin R. Flaherty; Athol U. Wells; Vincent Cottin; Anand Devaraj; Simon Walsh; Yoshikazu Inoue; Luca Richeldi; Martin Kolb; Kay Tetzlaff; Susanne Stowasser; Carl Coeck; Emmanuelle Clerisme-Beaty; Bernd Rosenstock; Manuel Quaresma; Thomas Haeufel; Rainer-Georg Goeldner; Rozsa Schlenker‐Herceg; Kevin K. Brown

doi:10.1056/nejmoa1908681

Abstract

In patients with progressive fibrosing interstitial lung diseases, the annual rate of decline in the FVC was significantly lower among patients who received nintedanib than among those who received placebo. Diarrhea was a common adverse event. (Funded by Boehringer Ingelheim; INBUILD ClinicalTrials.gov number, NCT02999178.).

Keywords

NintedanibIdiopathic pulmonary fibrosisMedicineLungFibrosisTyrosine-kinase inhibitorInterstitial lung diseasePathologyInternal medicine

MeSH Terms

AgedDiarrheaDisease ProgressionDouble-Blind MethodFemaleHumansIdiopathic Pulmonary FibrosisIndolesMaleMiddle AgedProtein Kinase InhibitorsVital Capacity

Affiliated Institutions

Related Publications

Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease

Oliver Distler , Kristin B. Highland , Martina Gahlemann +12 more

Among patients with ILD associated with systemic sclerosis, the annual rate of decline in FVC was lower with nintedanib than with placebo; no clinical benefit of nintedanib was ...

2019 New England Journal of Medicine 1463 citations

Predicting Survival in Idiopathic Pulmonary Fibrosis

Talmadge E. King , Janet A. Tooze , Marvin I. Schwarz +2 more

Our purpose was to identify clinical, radiological and physiological (CRP) determinants of survival and to develop a CRP scoring system that predicts survival in newly diagnosed...

2001 American Journal of Respiratory and C... 842 citations

Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

Ganesh Raghu , Martine Rémy-Jardin , Luca Richeldi +38 more

<b>Background:</b> This American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Asociación Latinoamericana de Tórax guideline updates prior id...

2022 American Journal of Respiratory and C... 2166 citations

The epidemiology of interstitial lung diseases.

David Coultas , RE Zumwalt , William C. Black +1 more

Little epidemiologic data are available on the occurrence of interstitial lung diseases (ILDs) in the general population. To describe the prevalence and incidence of ILDs a popu...

1994 American Journal of Respiratory and C... 934 citations

Idiopathic Pulmonary Fibrosis

William W. Douglas , Jay H. Ryu , Darrell R. Schroeder

The clinical records of 487 patients seen at Mayo Clinic Rochester (MCR) during 1994 through 1996 who were diagnosed as having idiopathic pulmonary fibrosis of the usual interst...

2000 American Journal of Respiratory and C... 259 citations

Publication Info

Year: 2019
Type: article
Volume: 381
Issue: 18
Pages: 1718-1727
Citations: 2097
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2097

OpenAlex

105

Influential

1882

CrossRef

Cite This

APA Style

                            
                                
                                    Kevin R. Flaherty, 
                                
                                    Athol U. Wells, 
                                
                                    Vincent Cottin
                                
                                et al.
                            
                            (2019). 
                            Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. 
                            New England Journal of Medicine
                            , 381
                            (18)
                            , 1718-1727.
                            https://doi.org/10.1056/nejmoa1908681
                        

Identifiers

DOI: 10.1056/nejmoa1908681
PMID: 31566307

Data Quality

Data completeness: 90%